Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease - Test2 - elhamkhani - TriplyDB

Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease

Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease

http://www.wikidata.org/entity/Q28344943

about

Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease Thalidomide and thalidomide analogues for induction of remission in Crohn's disease Effective treatment of gastrointestinal bleeding with thalidomide--Chances and limitations Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study.Effects of immunomodulatory drugs on TNF-α and IL-12 production by purified epidermal langerhans cells and peritoneal macrophages.New insights to occult gastrointestinal bleeding: From pathophysiology to therapeutics.Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production.Inflammatory bowel disease: clinical aspects and treatments.Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding.Treatment of pediatric refractory Crohn's disease with thalidomide.Antitumour necrosis factor therapy in Crohn's disease.Thalidomide and its derivatives: emerging from the wilderness.Differential angiogenic regulation of experimental colitis.Thalidomide for treatment of severe intestinal bleeding.Novel biological strategies in inflammatory bowel diseases.Herb-Partitioned Moxibustion Regulates the TLR2/NF-κB Signaling Pathway in a Rat Model of Ulcerative Colitis.Management of ulcerative colitis and Crohn's disease.The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.Apoptosis as a therapeutic tool in IBD?The role of TNFalpha in ulcerative colitis.HIF-1α and HIF-2α induced angiogenesis in gastrointestinal vascular malformation and reversed by thalidomide.Recent advances in the medical therapy of Crohn's disease in childhood.Treatment of inflammatory bowel disease: a review of medical therapy.Thalidomide: mechanisms of action.Colonic treatments and targets: issues and opportunities.Thalidomide for inflammatory bowel disease: Systematic review.TNF-alpha and neuropathic pain--a review.Review article: the role of non-biological drugs in refractory inflammatory bowel disease.Thalidomide: an old drug with new action.Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease.The clinical implications of thalidomide in inflammatory bowel diseases.Emerging biologics in inflammatory bowel disease.Drug Repositioning in Inflammatory Bowel Disease Based on Genetic Information.Thalidomide induces mucosal healing in Crohn's disease: case report Compromised neuroimmune status in rats with experimental colitis.Etanercept in erythema nodosum leprosum.An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.Tumor necrosis factor receptor type-1 in sensory neurons contributes to induction of chronic enhancement of inflammatory hyperalgesia in rat.Portulaca Extract Attenuates Development of Dextran Sulfate Sodium Induced Colitis in Mice through Activation of PPARγ.Thalidomide-induced angiopoietin 2, Notch1 and Dll4 downregulation under hypoxic condition in tissues with gastrointestinal vascular malformation and human umbilical vein endothelial cells.

P2860

Q24241489-30248482-C0A7-42F3-8709-7E870CEC079F Q24241766-5545CAD0-32E4-4D7C-9C31-AE0A16272DED Q26752740-0234747A-0A40-43A7-967D-71E7D64D94A5 Q33632574-D7817A8E-DF98-41B7-A197-7F51B84B5AC2 Q33806405-5863C31A-A72E-4E93-AB89-AE3C18EDA3AC Q34048017-ADC41886-494A-41D4-BD5F-06C92093A96F Q34098863-AB040FC6-1B86-4C94-8B16-F2D2103F0BC6 Q34431476-51C92B43-ED1E-4E20-85B5-1B6E2BB99501 Q34606176-77CE7356-E9F1-4E07-8CE9-2AA69274D32E Q34744824-1B46D16A-CB30-4338-A92D-FE3A090FE2D5 Q34974734-F4C0C169-2B58-40C9-A340-9BBDF4E8AC27 Q35107977-B5596FF3-9631-4FF0-9D69-0F6830EB664A Q35569803-BF5E40F0-51C1-4206-B61B-FA9D9DC2AD23 Q35596432-19057D47-AD2A-407A-B6DF-99173F81BABE Q35787653-BD3B5DC5-ECCF-4231-9F08-F5E134D3B350 Q35962379-2433D311-1E6B-47A3-BBAF-E5F03D49C2E6 Q36004867-5AFE3AF7-BF75-4611-9E74-94ADECEF1731 Q36612613-20F63BE8-592F-4AAF-A6B7-9150995B1310 Q36631420-10738966-855F-4535-B351-44E32AB493D8 Q36849148-CBB5349A-4BEB-4158-AB15-8183849A816A Q36955730-F738037F-3D1F-4774-A3A9-8273CD82DBA0 Q36968175-C405F2B6-3C55-47D1-B80A-6B06F4DA8A08 Q37058862-20109C29-044A-432E-8A14-9CFC8D26F48B Q37147933-9D10E29A-CC76-4E3F-B559-9A1DDBDD4C66 Q37530912-B973275E-CA71-4273-9002-6C7F54F11798 Q37605607-067089F3-85AC-41E1-B87D-98B964C13E7C Q37732472-FE8F66DB-BCD7-4FB7-B930-4A7E5C6F1492 Q37817487-2FBC059F-1AA4-420F-BE89-9E0DFAC7A1BA Q37974744-C98FE8EF-9E72-4835-AA10-7F94F441127A Q38413494-15775A79-A3AF-4544-9287-2F8948D43778 Q38417116-3A13C127-8834-4B07-B009-DF3CE4F4CAF3 Q39004625-3BE917E7-D32A-47CD-8B6F-8D5655EB64F7 Q39278136-00193F92-AFD1-44BA-A040-F285E307EE05 Q39754466-BEC069EF-F8F2-47A9-96D6-1EF13C018831 Q40563433-A6C8A157-075C-4A1F-9352-24F7DF3AFC76 Q41680121-4A793414-7295-4170-8C0D-22B68FEB152A Q44006206-CB5DB778-DB2D-4F06-B772-567D7DE96156 Q44444724-AC2C32BE-C04C-4CF2-9B1B-9BD00D1BDB3D Q50317594-31A1A1D7-5752-4E03-A313-FC759A2D09D3 Q53083368-79ECDC56-2A0F-4FE1-82E0-62B4AA81BDE0

P2860

Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease

http://www.wikidata.org/entity/Q28344943

description

2002 nî lūn-bûn

@nan

2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Thalidomide reduces tumour nec ...... chronic active Crohn's disease

@ast

Thalidomide reduces tumour nec ...... chronic active Crohn's disease

@en

Thalidomide reduces tumour nec ...... chronic active Crohn's disease

@nl

type

label

Thalidomide reduces tumour nec ...... chronic active Crohn's disease

@ast

Thalidomide reduces tumour nec ...... chronic active Crohn's disease

@en

Thalidomide reduces tumour nec ...... chronic active Crohn's disease

@nl

prefLabel

Thalidomide reduces tumour nec ...... chronic active Crohn's disease

@ast

Thalidomide reduces tumour nec ...... chronic active Crohn's disease

@en

Thalidomide reduces tumour nec ...... chronic active Crohn's disease

@nl

P1433

Q28344943-015E85F6-6CB2-4BE4-B520-8E4A7C4B9C23

P1476

Q28344943-25925740-64C6-480D-8835-3F380C9C4722

P2093

Q28344943-47D6A54A-18B9-4425-8D71-42FE8D06D74C

Q28344943-8EDDD802-169E-4839-9620-F0DB07D952FA

Q28344943-AB822FC4-08D3-4C96-80A3-C265EBABD8AD

P2860

Q28344943-001D5C2D-0B39-4AB6-BA9E-3BF7719D4CE8

Q28344943-05272E9B-6980-4B26-8713-1CD203E22D81

Q28344943-0599723E-184C-4FA4-B727-D193BED01DC4

Q28344943-0A00F15D-05E4-4BC9-B4C0-654FE7426738

Q28344943-18C2EE2B-A017-4B5A-826B-CBAD6CD4EC1B

Q28344943-1C6A2E28-259D-41FE-9735-0262612D949A

Q28344943-202BEF43-C2DF-4A5B-9C40-153B9FAC75C3

Q28344943-228085D5-A850-4938-BCC1-AAE503D5AA70

Q28344943-252339B0-AB6F-4799-958E-F90F411E9119

Q28344943-2F942A9C-37AB-4E03-824B-6F935C9CD84A

P304

Q28344943-1D7530F6-364A-499F-865F-BF87A2D8A732

P31

Q28344943-50E9C6CA-C4AF-4BF8-86EF-BC0CFC12EF7E

P3181

Q28344943-55790615-578B-4F83-9FE9-D1EA43E1F222

P356

Q28344943-62852998-1230-416E-8688-D443FBAE3F20

P407

Q28344943-A64427CC-04CC-436D-A35F-4A2A326BAC98

P433

Q28344943-E308C00B-9EDA-4DE5-9354-2F14B0C913D7

P478

Q28344943-62CECD55-ACBA-44B8-AD15-31629DC82A71

P577

Q28344943-C8A3B18C-269A-45A8-975B-CE7C496EBA4A

P698

Q28344943-12A8771C-0FA7-4E74-9305-A63539C13C6D

P921

Q28344943-1FD0B6F9-89BA-404E-BC4B-CF6D8BC3EE9B

Q28344943-32404610-0A07-4DA6-8E9D-889425894F6D

Q28344943-F8BB2A03-560A-40AF-9192-41FE48DCF8E4

Q28344943-d9735e50-6371-4589-82dc-f2233368a498

Q28344943-df59c285-7748-4145-9481-3558803886a4

P932

Q28344943-99FD4344-4755-4205-BB0C-EFC0E9BBF66B

P3181

P356

P1433

P1476

Thalidomide reduces tumour nec ...... chronic active Crohn's disease

@en

P2093

H Lochs

http://www.w3.org/2001/XMLSchema#string

J Bauditz

http://www.w3.org/2001/XMLSchema#string

S Wedel

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease

In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.

Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.

Thalidomide: a novel therapy for microsporidiosis.

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial.

Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)

Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor.

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

Inflammatory properties of recombinant tumor necrosis factor in rabbit skin in vivo.

P304

196-200

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1124943

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/GUT.50.2.196

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11788559

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease

P932

1773116

http://www.w3.org/2001/XMLSchema#string